# US 2023/0147121 A1 · Compositions of solid forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0147121 A1
- Document ID: US20230147121A1
- Status: Published application
- Kind: A1
- Application number: 18/057,633
- Filed: 2022-11-21
- Published: 2023-05-11
- Earliest claimed: 2019-08-09
- Assignees: Springworks Therapeutics, Inc.
- Applicants: SpringWorks Therapeutics, Inc.
- Inventors: Kristin PATTERSON; Todd Webster SHEARER
- Web page: https://patentgrep.com/patent/US20230147121A1

## CPC

- C07D 233/88: Nitrogen atoms, e.g. allantoin
- A61K 31/404: Indoles, e.g. pindolol
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

## Claims

### Claim at position 1

1-144. (canceled)

### Claim 145

A pharmaceutical composition comprising a solid form of nirogacestat or salt thereof wherein the solid form is characterized by a differential scanning calorimetry profile comprising a phase transition between about 39° C. and about 275° C.

### Claim 146 (depends on 145)

The pharmaceutical composition of claim 145 wherein the differential scanning calorimetry profile comprises a phase transition between about 212° C. and about 275° C.

### Claim 147 (depends on 145)

The pharmaceutical composition of claim 145 wherein the differential scanning calorimetry profile comprises a phase transition between about 229° C. and about 275° C.

### Claim 148 (depends on 145)

The pharmaceutical composition of claim 145 wherein the differential scanning calorimetry profile comprises a phase transition at about 275° C.

### Claim 149 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition provides a mean time to maximum drug plasma concentration (Tmax) of more than about 0.5 hour.

### Claim 150 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition provides a mean time to maximum drug plasma concentration (Tmax) of more than about 1 hour.

### Claim 151 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition comprises about 50 mg nirogacestat or salt thereof.

### Claim 152 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition comprises about 50 mg nirogacestat or salt thereof and is administered to a patient diagnosed with a desmoid tumor.

### Claim 153 (depends on 145)

The pharmaceutical composition of claim 145 wherein administration of one or more oral tablets to a patient in need thereof provides a mean maximum drug plasma concentration (Cmax) of about 50 ng/ml to about 1500 ng/ml.

### Claim 154 (depends on 145)

The pharmaceutical composition of claim 145 wherein administration of one or more oral tablets to a patient in need thereof provides an in vivo area under the plasma curve (AUCinf) of about 50 ng h/ml to about 6500 ng h/ml.

### Claim 155 (depends on 145)

The pharmaceutical composition of claim 145 wherein administration of one or more oral tablets to a patient in need thereof provides a mean maximum drug plasma concentration (Cmax) of about 250 ng/ml to about 1200 ng/ml.

### Claim 156 (depends on 145)

The pharmaceutical composition of claim 145 wherein administration of one or more oral tablets to a patient in need thereof provides an in vivo area under the plasma curve (AUCinf) of about 800 ng h/ml to about 6000 ng h/ml.

### Claim 157 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and provides a mean maximum drug plasma concentration (Cmax) of about 50 ng/ml to about 550 ng/ml.

### Claim 158 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and provides an in vivo area under the plasma curve (AUCinf) of about 50 ng h/ml to about 300 ng h/ml.

### Claim 159 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and is administered as one or more dosages to provide a mean maximum drug plasma concentration (Cmax) of about 500 ng/ml to about 1200 ng/ml.

### Claim 160 (depends on 145)

The pharmaceutical composition of claim 145 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and is administered as one or more dosages to provide an in vivo area under the plasma curve (AUCinf) of about 2000 ng h/ml to about 5000 ng h/ml.

### Claim 161 (depends on 148)

The pharmaceutical composition of claim 148 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and provides a mean maximum drug plasma concentration (Cmax) of about 50 ng/ml to about 550 ng/ml.

### Claim 162 (depends on 148)

The pharmaceutical composition of claim 148 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and provides an in vivo area under the plasma curve (AUCinf) of about 50 ng h/ml to about 300 ng h/ml.

### Claim 163 (depends on 148)

The pharmaceutical composition of claim 148 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and is administered as one or more dosages to provide a mean maximum drug plasma concentration (Cmax) of about 500 ng/ml to about 1200 ng/ml.

### Claim 164 (depends on 148)

The pharmaceutical composition of claim 148 wherein the composition is an oral dosage form comprising about 50 mg nirogacestat or salt thereof and is administered as one or more dosages to provide an in vivo area under the plasma curve (AUCinf) of about 2000 ng h/ml to about 5000 ng h/ml.
